Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 6/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756842 | 0.90 | NUAK1 (0.45) | CSF1RCDK4CDK6STAT6JAK2 | |
| SCHEMBL13756768 | 0.86 | NUAK1 (0.44) | CDK4JAK2EPHX2BRD4CCNA2 | |
| SCHEMBL13756766 | 0.86 | NTRK1 (0.49) | JAK2LRRK2NTRK1CCNA2CDK2 | |
| SCHEMBL13756843 | 0.82 | NUAK1 (0.47) | CSF1RJAK2BRD4CCNA2CDK2 | |
| SCHEMBL1654907 | 0.82 | RPS6KA3 (0.56) | CDK4JAK2BRD4 | |
| SCHEMBL13756769 | 0.82 | NUAK1 (0.54) | CSF1RCDK4JAK2BRD4CCNA2 | |
| SCHEMBL13756696 | 0.80 | CSF1R (0.46) | CSF1RCDK4CDK6STAT6JAK2 | |
| SCHEMBL13756800 | 0.80 | CDK2 (0.46) | CDK4JAK2BRD4CDK2 | |
| SCHEMBL13756756 | 0.79 | PTGS2 (0.48) | CDK4STAT6JAK2BRD4CDK2 | |
| SCHEMBL13756839 | 0.78 | JAK2 (0.55) | CDK4CDK6STAT6JAK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | CSF1R 1606/4885CDK4 186/4885CDK6 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.